Spots Global Cancer Trial Database for A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Official Title: A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Study ID: NCT02659020
Conditions
Study Description
Brief Summary: The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Detailed Description:
Keywords
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Medical Center, Santa Monica, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Georgia Cancer Specialists PC, Atlanta, Georgia, United States
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University Medical School, Saint Louis, Missouri, United States
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
Monter Cancer Center, Lake Success, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Ohio State University Medical Center, Columbus, Ohio, United States
Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Utah Cancer Specialists, Salt Lake City, Utah, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Institut Bergonie, Bordeaux, , France
Centre Oscar Lambret, Lille Cedex, , France
Gustave Roussy, Villejuif Cedex, , France
Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany
Klinikum der Universität München, München, Bayern, Germany
Universitätsklinikum Regensburg, Regensburg, Bayern, Germany
Helios Klinikum Bad Saarow, Bad Saarow, Brandenburg, Germany
Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
HELIOS Klinikum Berlin-Buch, Berlin, , Germany
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, , Hungary
Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
Rambam Medical Center, Haifa, , Israel
Rabin Medical Center, Petah Tiqva, , Israel
Tel Aviv Sourasky Medical Center, Tel Aviv, , Israel
Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro, Candiolo, Torino, Italy
Humanitas Gradenigo, Torino, , Italy
Centrum Onkologii-Instytut im Marii Sklodowskiej-Curie, Warszawa, , Poland
Hospital Universitari Vall d'Hebron, Barcelona, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain
Hospital Universitario Virgen del Rocio, Sevilla, , Spain
University College Hospital - London, London, Greater London, United Kingdom
Royal Marsden NHS Trust, London, Greater London, United Kingdom
Clatterbridge Cancer Centre, Bebbington, Merseyside, United Kingdom
Western General Hospital, Edinburgh, Scotland, United Kingdom
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
